Vectura Group PLC’s (VEC) Overweight Rating Reaffirmed at J P Morgan Chase & Co
J P Morgan Chase & Co reaffirmed their overweight rating on shares of Vectura Group PLC (LON:VEC) in a research note issued to investors on Thursday, StockTargetPrices.com reports.
Several other research firms also recently weighed in on VEC. Shore Capital reissued a buy rating on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Peel Hunt reissued a hold rating and issued a GBX 160 ($2.10) target price on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Numis Securities Ltd reissued a buy rating and issued a GBX 205 ($2.70) target price on shares of Vectura Group PLC in a research report on Thursday, October 5th. Panmure Gordon reaffirmed a buy rating on shares of Vectura Group PLC in a research report on Wednesday, August 30th. Finally, Citigroup Inc. lowered their price objective on shares of Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating on the stock in a research report on Monday, September 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Vectura Group PLC currently has an average rating of Buy and an average target price of GBX 189.67 ($2.49).
Vectura Group PLC (LON VEC) opened at GBX 91.10 ($1.20) on Thursday. Vectura Group PLC has a 1 year low of GBX 86.50 ($1.14) and a 1 year high of GBX 166.97 ($2.20).
TRADEMARK VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://theolympiareport.com/2017/11/20/vectura-group-plcs-vec-overweight-rating-reaffirmed-at-j-p-morgan-chase-co.html.
In other Vectura Group PLC news, insider Bruno Angelici bought 70,000 shares of Vectura Group PLC stock in a transaction on Tuesday, September 12th. The stock was purchased at an average cost of GBX 99 ($1.30) per share, for a total transaction of £69,300 ($91,148.23). Also, insider Andrew Derodra bought 82,000 shares of Vectura Group PLC stock in a transaction on Thursday, September 7th. The stock was acquired at an average price of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,066.95). Insiders acquired 152,456 shares of company stock valued at $14,354,880 over the last quarter.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.